The Rise of 4DMedical Ltd in a Struggling Healthcare Sector
The share price of 4DMedical Ltd (ASX: 4DX) stands at $3.95, marking a 1.5% decline for the day but reflecting a remarkable 1,173% increase over the past 12 months. This ASX 200 healthcare stock is standing out in a sector that has been underperforming significantly for many months. In fact, healthcare has been the worst-performing sector among the 11 ASX 200 market sectors over the last year, with a drop of 39%. The question arises: why are 4DMedical shares defying the trend?
A Unique Growth Story
4DMedical shares have seen a significant upward trajectory as the respiratory imaging technology company continues to make substantial progress in its growth. According to Samy Sriram, a market analyst at online investment platform Stake, the company’s performance is built on a series of catalysts that contrast sharply with the challenges facing its peers.
ASX 200 healthcare companies are currently dealing with numerous headwinds, including currency challenges for those reporting in US dollars and the potential for further interest rate hikes in Australia. Additionally, cost-of-living pressures are prompting people to delay treatments such as surgeries. Other factors like higher shipping costs due to the Iran war, new caps on insurance payouts in some countries, and increased staff wages are also affecting the sector.
However, 4DMedical has successfully navigated one of the biggest hurdles for ASX biotechs today: regulatory uncertainty in the United States. Amid leadership changes at the US Food and Drug Administration (FDA), there are conflicting signals on future approval standards. A US rare diseases advocacy organization notes that uncertainty has become so great that biotechs are finding it difficult to raise funding.
Sriram highlighted that while other ASX healthcare stocks are being negatively impacted by FDA uncertainty under Trump, 4DX had already cleared this hurdle. In September 2025, 4DMedical received FDA 510(k) clearance for its CT:VQ platform. The company also secured a one-year contract with GlaxoSmithKline (LSE: GSK), starting in May 2026, to provide lung imaging biomarkers for pharmaceutical clinical trials.
Understanding CT:VQ Technology
4DMedical describes CT:VQ as the world’s first non-contrast post-processing technology that transforms routine chest CTs into quantitative, lobar ventilation and perfusion maps without the need for patients to be injected with contrast agents or radioisotopes. It is a software-as-a-service (SaaS) system compatible with the 14,500 CT scanners already installed across the US.
Sriram noted that 4DMedical shares are bucking the trend because the company is in a different stage of its regulatory and commercial journey than its healthcare sector peers. She stated that the headwinds impacting CSL Ltd (ASX: CSL), Cochlear Ltd (ASX: COH), and ResMed CDI (ASX: RMD) do not apply to a company that cracked the US market open from scratch. It is a pure growth story in a sector that’s otherwise in a value reset.
Recent Regulatory Approvals and Market Expansion
Last month, 4DMedical announced several other regulatory approvals, including certification for CT:VQ in the United Kingdom. The company mentioned that UK clearance opens access to one of the world’s most developed diagnostic imaging markets, with millions of chest CT scans performed annually across respiratory, oncology, and acute care pathways.
Should You Invest in 4DMedical Shares?
This ASX 200 healthcare share is popular with Australian investors. Over the past 30 days, 4DMedical shares were the most traded ASX 200 healthcare stock on Stake, with 70% of orders being buys. There is a consensus hold rating among three analysts on the CommSec trading platform today. Stuart Bromley from Medallion Financial Group also has a hold rating on 4DMedical shares.
Bromley noted that 4DMedical has a strong regulatory moat in the US and commented that in a relatively short time since the US Food and Drug Administration approved its CT:VQ product, US hospitals are adopting it, including the highly renowned Mayo Clinic. Also, 4DX has been included in the S&P/ASX200 Index, which should generate more interest in the company.
4DMedical shares ascended into the ASX 200 on 20 April in place of Insignia Financial, which was acquired by Daintree BidCo.
Final Considerations
Before investing in 4DMedical shares, it’s essential to consider various factors. Motley Fool investing expert Scott Phillips recently revealed what he believes are the 5 best stocks for investors to buy right now, and 4DMedical wasn’t one of them. The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled, or even more.
Currently, Scott thinks there are 5 stocks that may be better buys. For more information, you can see the 5 Stocks.
